A tiny biotech’s plot to frustrate Regeneron and Sanofi runs into a safety problem

Esperion Therapeutics () cleared a key hurdle in its quest to drive a wedge into the market for cardiovascular drugs, establishing that its drug lowered bad cholesterol in a large trial. But more patients taking the drug died than those getting placebo, raising questions about whether Esperion’s therapy will prove safe enough to win approval.